Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Varian Halcyon System Gets 510(k) Approval From The FDA

Published 07/04/2017, 08:07 AM
Updated 07/09/2023, 06:31 AM

Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. (NYSE:VAR) recently announced the 510(k) approval for its Halcyon system. The Halcyon radiotherapy treatment system has been designed to offer cost-effective cancer care worldwide. In June Varian showcased the Halcyon system at the 2017 DEGRO meeting, the German radiation oncology society, in Berlin.

The Halcyon system streamlines every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). The system has received both 510(k) clearance and a CE mark from the European directive. Notably, Varian can initiate the selling process of the Halcyon system in the U.S. However, the system requires Eclipse 15.1.1 planning software, which is currently pending for a 510(k) approval.

Halcyon system has a user-friendly design and it automates, streamlines and simplifies almost every aspect of cancer treatment. Per management, the system offers treatment for prostate, breast, head & neck, and most other forms of cancer.

We note that the global radiotherapy market is expected to reach a worth of $7,544.8 million by 2020, at a CAGR of 6.2%. Taking the bountiful prospects in the global niche space into consideration, the latest development should boost investor confidence.

Price Movement

Varian has a Zacks Rank #2 (Buy).

The company has had an impressive run on the bourse over the last one month. Varian has gained almost 1.02%, higher than the Zacks classified Medical - Instruments sub-industry’s decline of 1.3%. Furthermore, the stock’s price level was higher than the S&P 500’s negative return of 0.6% over the same time frame.

Meanwhile, the company’s recent earnings estimates have been mixed at best. The current year has seen one analyst move north in the past two months, while next year estimates have seen two upward revisions, compared to no movement in the opposite direction.

This has had a significant impact on the consensus estimate, as the current quarter estimates lost roughly 1% over the last two months, while next year estimates increased 0.9%.

A few other top-ranked stocks in the broader medical sector are Inogen Inc. (NASDAQ:INGN) , Mesa Laboratories, Inc. (NASDAQ:MLAB) and Edap Tms S.a. (NASDAQ:EDAP) . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 100%.

Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. Notably, the stock represents an impressive one-year return of 16.7%.

Edap Tms represents an impressive one-year return of 2.2% for the last three months. The company provided a solid earnings surprise of 533.3% in the last reported quarter.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>



Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report

EDAP TMS S.A. (EDAP): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.